Publication Cover
Synthetic Communications
An International Journal for Rapid Communication of Synthetic Organic Chemistry
Volume 50, 2020 - Issue 3
201
Views
2
CrossRef citations to date
0
Altmetric
SYNTHETIC COMMUNICATIONS REVIEWS

Dibenzofuran annulated 1-azepines: Synthesis and cytotoxicity

ORCID Icon, , &
Pages 438-445 | Received 08 Sep 2019, Published online: 26 Dec 2019
 

Abstract

The 2,3,4,5-tetrahydro-1H-benzo[2,3]benzofuro[6,5-b]azepine skeleton was built starting from dibenzofuran via 3-aminodibenzofuran, creating the 5-methylene-substituted azepine ring by an intramolecular Heck cyclization. Subsequent modifications led to the endocyclic 4,5-unsaturated analog, the dihydro product, and N-methyl and N-acylated derivatives. All the compounds were obtained in high yields and were fully characterized. Preliminary proliferation assays in a wild-type and a cisplatin-resistant human ovarian carcinoma cell line (A2780 and A2780cisR respectively) indicated that these compounds are moderately cytotoxic, with no significant differences associated with cisplatin resistance. The N-acetyl-5-methylene analog 3 (IC50 = 10 μM), the only one with an exocyclic double bond in conjugation with a benzene ring, was at least twice as active as any other member of the series, suggesting that this structural feature might be associated with higher cytotoxicity.

GRAPHICAL ABSTRACT

Additional information

Funding

Authors TY and BKC are grateful to CONICYT (Chile) for providing funds through FONDECYT postdoctoral grant 3150474.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.